Cargando…

VRK1 promotes cisplatin resistance by up-regulating c-MYC via c-Jun activation and serves as a therapeutic target in esophageal squamous cell carcinoma

Esophageal squamous cell carcinoma (ESCC) is a common malignant disease characterized by poor prognosis. Chemoresistance remains a major cause of ESCC relapse. Vaccinia-related kinase 1 (VRK1) has previously been identified as a cancer-related gene. However, there is little research demonstrating an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhen-Chuan, Cao, Kuo, Xiao, Zhao-Hua, Qiao, Liang, Wang, Xue-Qing, Shang, Bin, Jia, Yang, Wang, Zhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630360/ https://www.ncbi.nlm.nih.gov/pubmed/29029460 http://dx.doi.org/10.18632/oncotarget.20020

Ejemplares similares

SNHG17, as an EMT‐related lncRNA, promotes the expression of c‐Myc by binding to c‐Jun in esophageal squamous cell carcinoma
por: Shen, Supeng, et al.
Publicado: (2021)

C‐Jun N‐terminal kinase signalling pathway in response to cisplatin
por: Yan, Dong, et al.
Publicado: (2016)

VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
por: Shields, Julie A., et al.
Publicado: (2022)

Differentiation-Associated Genes Regulated by c-Jun and Decreased in the Progression of Esophageal Squamous Cell Carcinoma
por: Luo, Aiping, et al.
Publicado: (2014)

The C/H3 Domain of p300 Is Required to Protect VRK1 and VRK2 from their Downregulation Induced by p53
por: Valbuena, Alberto, et al.
Publicado: (2008)

Differential Inhibitor Sensitivity between Human Kinases VRK1 and VRK2
por: Vázquez-Cedeira, Marta, et al.
Publicado: (2011)

NS1-binding protein radiosensitizes esophageal squamous cell carcinoma by transcriptionally suppressing c-Myc
por: Wang, Yuwen, et al.
Publicado: (2018)

Comparative Interactomes of VRK1 and VRK3 with Their Distinct Roles in the Cell Cycle of Liver Cancer
por: Lee, Namgyu, et al.
Publicado: (2017)

Selection and Characterization of a DNA Aptamer That Can Discriminate between cJun/cJun and cJun/cFos
por: Walters, Ryan D., et al.
Publicado: (2014)

VRK1 as a synthetic lethal target in VRK2 promoter–methylated cancers of the nervous system
por: So, Jonathan, et al.
Publicado: (2022)

Targeting MUC1-C reverses the cisplatin resistance of esophageal squamous cell carcinoma in vitro and in vivo
por: Zhao, Yong-Qiang, et al.
Publicado: (2021)

Proteomics Identification of Nuclear Ran GTPase as an Inhibitor of Human VRK1 and VRK2 (Vaccinia-related Kinase) Activities
por: Sanz-García, Marta, et al.
Publicado: (2008)

Downregulation of VRK1 Inhibits Progression of Lung Squamous Cell Carcinoma through DNA Damage
por: Du, Ning, et al.
Publicado: (2023)

Cdx1 and c-Myc Foster the Initiation of Transdifferentiation of the Normal Esophageal Squamous Epithelium toward Barrett's Esophagus
por: Stairs, Douglas B., et al.
Publicado: (2008)

SREBP2 is upregulated in esophageal squamous cell carcinoma and co-operates with c-Myc to regulate HMGCR expression
por: Zhong, Chenxi, et al.
Publicado: (2019)

Autonomous pick-and-place using the dVRK
por: D’Ettorre, Claudia, et al.
Publicado: (2021)

Inhibition of MUC1-C entering nuclear suppresses MYC expression and attenuates malignant growth in esophageal squamous cell carcinoma
por: Xin, Zhongwei, et al.
Publicado: (2018)

VRK1 Kinase Activity Modulating Histone H4K16 Acetylation Inhibited by SIRT2 and VRK-IN-1
por: Monte-Serrano, Eva, et al.
Publicado: (2023)

Shenmai Injection Supresses Glycolysis and Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant A549/DDP Cells via the AKT-mTOR-c-Myc Signaling Pathway
por: Sun, Ye, et al.
Publicado: (2020)

Protein Synthesis Inhibition and Activation of the c-Jun N-Terminal Kinase Are Potential Contributors to Cisplatin Ototoxicity
por: Nicholas, Brian D., et al.
Publicado: (2017)

Downregulation of VRK1 reduces the expression of BANF1 and suppresses the proliferative and migratory activity of esophageal cancer cells
por: Ren, Zhenzhen, et al.
Publicado: (2020)

BAALC‐AS1/G3BP2/c‐Myc feedback loop promotes cell proliferation in esophageal squamous cell carcinoma
por: Zhang, Hongyue, et al.
Publicado: (2021)

NEDD4L inhibits cell viability, cell cycle progression, and glutamine metabolism in esophageal squamous cell carcinoma via ubiquitination of c-Myc: NEDD4L and c-Myc coordinate to regulate ESCC
por: Cheng, Wei, et al.
Publicado: (2022)

Functional characterization of lysosomal interaction of Akt with VRK2
por: Hirata, Noriyuki, et al.
Publicado: (2018)

Targeting EFNA1 suppresses tumor progression via the cMYC-modulated cell cycle and autophagy in esophageal squamous cell carcinoma
por: Jiang, Houxiang, et al.
Publicado: (2023)

Vrk1 partial Knockdown in Mice Results in Reduced Brain Weight and Mild Motor Dysfunction, and Indicates Neuronal VRK1 Target Pathways
por: Vinograd-Byk, Hadar, et al.
Publicado: (2018)

VRK1 functional insufficiency due to alterations in protein stability or kinase activity of human VRK1 pathogenic variants implicated in neuromotor syndromes
por: Martín-Doncel, Elena, et al.
Publicado: (2019)

Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas
Publicado: (1998)

Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas.
por: Volm, M., et al.
Publicado: (1998)

Upregulation of miR-21 in Cisplatin Resistant Ovarian Cancer via JNK-1/c-Jun Pathway
por: Echevarría-Vargas, Ileabett M., et al.
Publicado: (2014)

Overexpression of miR-216b sensitizes NSCLC cells to cisplatin-induced apoptosis by targeting c-Jun
por: Huang, Gang, et al.
Publicado: (2017)

HSP90 Inhibitor Ganetespib (STA-9090) Inhibits Tumor Growth in c-Myc-Dependent Esophageal Squamous Cell Carcinoma
por: Guan, Liuliu, et al.
Publicado: (2020)

Upregulation of the c-MYC oncogene and adjacent long noncoding RNAs PVT1 and CCAT1 in esophageal squamous cell carcinoma
por: Roohinejad, Zahra, et al.
Publicado: (2023)

Identification and validation of the role of c-Myc in head and neck squamous cell carcinoma
por: Zhao, Sufeng, et al.
Publicado: (2022)

Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression.
por: Walker, T. L., et al.
Publicado: (1996)

Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis
por: Zhang, Peng, et al.
Publicado: (2016)

miR‐493 by regulating of c‐Jun targets Wnt5a/PD‐L1‐inducing esophageal cancer cell development
por: Bian, Wei, et al.
Publicado: (2021)

Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma
por: Robinson, Anthony M., et al.
Publicado: (2019)

ENKUR expression induced by chemically synthesized cinobufotalin suppresses malignant activities of hepatocellular carcinoma by modulating β-catenin/c-Jun/MYH9/USP7/c-Myc axis
por: Hou, Rentao, et al.
Publicado: (2022)

Transcriptional upregulation of c‐MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma
por: Hong, Jun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8nbf3va8ul3h0tlta4q1vmbg1e